Unknown

Dataset Information

0

The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma.


ABSTRACT: Glioblastoma (GBM) is a highly lethal cancer that is universally refractory to the standard multimodal therapies of surgical resection, radiation, and chemotherapy treatment. Temozolomide (TMZ) is currently the best chemotherapy agent for GBM, but the durability of response is epigenetically dependent and often short-lived secondary to tumor resistance. Therapies that can provide synergy to chemoradiation are desperately needed in GBM. There is accumulating evidence that adaptive resistance evolution in GBM is facilitated through treatment-induced epigenetic modifications. Epigenetic alterations of DNA methylation, histone modifications, and chromatin remodeling have all been implicated as mechanisms that enhance accessibility for transcriptional activation of genes that play critical roles in GBM resistance and lethality. Hence, understanding and targeting epigenetic modifications associated with GBM resistance is of utmost priority. In this review, we summarize the latest updates on the impact of epigenetic modifications on adaptive resistance evolution in GBM to therapy.

SUBMITTER: Wu Q 

PROVIDER: S-EPMC8347012 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6773736 | biostudies-literature
| S-EPMC6595545 | biostudies-literature
| S-EPMC8125972 | biostudies-literature
| S-EPMC5810480 | biostudies-literature
| S-EPMC8992632 | biostudies-literature
| S-EPMC8955587 | biostudies-literature
| S-EPMC10264773 | biostudies-literature
| S-EPMC7145008 | biostudies-literature
| S-EPMC6735723 | biostudies-literature
| S-EPMC1224216 | biostudies-other